{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-110681","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.664279+00:00","generated_at":"2026-05-15T10:57:54.982031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AN2 Therapeutics reports FY2025 net loss of $35.2M; $40M private placement extends runway into 2029","bullets":["Net loss for FY2025 was $35.2 million, compared to $51.3 million in FY2024.","Cash and investments at Dec 31, 2025: $60.0 million; private placement in March 2026 added ~$40 million gross.","Phase 2 study of oral epetraborole in polycythemia vera to begin 3Q26; data readouts possible from 4Q26.","Phase 2 investigator-initiated trial in M. abscessus lung disease enrollment expected 1Q26; topline late 2027.","Phase 1 first-in-human trial of AN2-502998 for Chagas nearing completion; initial data expected 1Q26."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-110681","json":"https://secwatch.observer/filing/0001193125-26-110681.json","markdown":"https://secwatch.observer/filing/0001193125-26-110681.md","text":"https://secwatch.observer/filing/0001193125-26-110681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/0001193125-26-110681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/antx-20260317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:57:54.982031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66ab51aea4c2a28657745dea491afbbedc9362e9","claim":"AN2 Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2025.","evidence_excerpt":"On March 17, 2026, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/0001193125-26-110681-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}